Integrative Validation of a Conserved BPGM Allosteric Dimer Pocket for Drug Repurposing in Sickle Cell Disease
ISEF · 2026 Computational Biology and Bioinformatics
Overview
Sickle cell disease (SCD) remains a major global health challenge, with no widely accessible targeted cure and most existing therapies focused on symptom management or partial disease modification. Elevated levels of 2,3-bisphosphoglycerate (2,3-BPG) reduce hemoglobin oxygen affinity, promoting hemoglobin S polymerization and red blood cell sickling. Bisphosphoglycerate mutase (BPGM), the key enzyme regulating 2,3-BPG levels in erythrocytes, represents a promising yet underexplored therapeutic target. This study aimed to validate a conserved allosteric pocket at the BPGM dimer interface and evaluate its potential for ligand binding. Structural characterization using computational analysis confirmed that the interface pocket exhibits favorable druggability features. A library of 1,600 FDA-approved drugs was screened using a hierarchical molecular docking workflow followed by MM-GBSA rescoring. Top candidates, including ketorolac, amlodipine, and avatrombopag, demonstrated stable binding at the interface during molecular dynamics simulations. However, their pharmacological profiles may limit suitability for chronic use in SCD. To identify more suitable candidates, a natural compound library was subsequently screened. The natural compound acarbose, an FDA-approved drug with a favorable safety profile, demonstrated stable binding and consistent interactions at the interface site in molecular dynamics simulations. Post-simulation analyses suggest that ligand binding at this region may influence protein dynamics consistent with an allosteric mechanism. These findings validate the BPGM dimer interface as a druggable allosteric site and identify clinically relevant scaffolds for further optimization and experimental evaluation as a potential antisickling strategy in SCD.
Awards (2)
- King Abdulaziz & his Companions Foundation for Giftedness and Creativity: NOT TO BE READ -- $200 cash prize for each Enrichment award recipient $200
- King Abdulaziz & his Companions Foundation for Giftedness and Creativity: Mawhiba Universal Enrichment Program awards (and a $200 cash prize) $200
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2019
A Novel Peptide Drug as a Therapeutic in Sickle Cell Anemia
ISEF · 2019
A Novel Approach on G6PD Enzyme Deficiency Treatment: Drug Repurposing
ISEF · 2019
Computational Screening of Small Molecules for Antibacterial Agents that Target T-Box Riboswitches
ISEF · 2018
Developing a Machine Learning Model to Identify Protein-Protein Interaction Hotspots to Facilitate Drug Discovery
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair